Payment overview · 2025
General Payments
$1,120.23
63 reported records · 23 companies
Healthcare provider profile · identity verified
Justin Lande
Allopathic & Osteopathic Physicians|Internal Medicine · DANVILLE, KY · NPI 1538542378
Verified facts
What the public records show
CMS Open Payments records show Justin Lande received $1,120.23 in general payments during 2025 across 63 reported records.
ABBVIE INC. accounted for 17.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Mounjaro, Ozempic, Qulipta, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 275 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 275 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 262 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 517 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $197.84 | 17.7% | 16 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $171.42 | 15.3% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $96.70 | 8.6% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $92.94 | 8.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $90.65 | 8.1% | 5 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $55.50 | 5.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.69 | 4.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $43.45 | 3.9% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.73 | 3.3% | 2 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $32.30 | 2.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.80 | 2.8% | 1 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $29.04 | 2.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $28.50 | 2.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.05 | 2.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.43 | 1.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.25 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.22 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.49 | 1.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.38 | 1.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.20 | 1.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $14.84 | 1.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $13.92 | 1.2% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $13.89 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,120.23 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $161.84 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $116.63 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $109.16 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $81.21 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $81.21 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $69.46 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $61.13 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $55.50 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.10 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $46.69 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $44.14 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $43.45 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $36.73 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $35.99 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.57 | 2 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $32.30 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.80 | 1 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $29.04 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $28.50 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $27.05 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $9.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 275 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 262 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 517 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 157 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
75 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
275 | 71 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
157 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
275 | 71 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
262 | 60 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
155 | 34 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
517 | 109 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
148 | 34 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1108 | 327 |
| Levothyroxine Sodium | Levothyroxine Sodium | 778 | 224 |
| Lisinopril | Lisinopril | 699 | 195 |
| Omeprazole | Omeprazole | 574 | 169 |
| Gabapentin | Gabapentin | 565 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 554 | 163 |
| Ozempic | Semaglutide | 517 | 109 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 504 | 167 |
| Losartan Potassium | Losartan Potassium | 481 | 149 |
| Pantoprazole Sodium | Pantoprazole Sodium | 444 | 127 |
| Metformin Hcl | Metformin Hcl | 359 | 103 |
| Nifedipine Er | Nifedipine | 320 | 89 |
| Trazodone Hcl | Trazodone Hcl | 319 | 86 |
| Montelukast Sodium | Montelukast Sodium | 313 | 97 |
| Escitalopram Oxalate | Escitalopram Oxalate | 277 | 72 |
| Jardiance | Empagliflozin | 275 | 71 |
| Carvedilol | Carvedilol | 273 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 273 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 273 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 83 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 269 | 92 |
| Mounjaro | Tirzepatide | 262 | 60 |
| Fluticasone Propionate | Fluticasone Propionate | 261 | 100 |
| Furosemide | Furosemide | 251 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 233 | 77 |
| Pravastatin Sodium | Pravastatin Sodium | 231 | 74 |
| Duloxetine Hcl | Duloxetine Hcl | 225 | 62 |
| Potassium Chloride | Potassium Chloride | 197 | 63 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 187 | 137 |
| Tramadol Hcl | Tramadol Hcl | 186 | 34 |
| Chlorthalidone | Chlorthalidone | 180 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 176 | 48 |
| Ezetimibe | Ezetimibe | 166 | 56 |
| Alendronate Sodium | Alendronate Sodium | 165 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 158 | 40 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 157 | 39 |
| Trulicity | Dulaglutide | 155 | 34 |
| Meloxicam | Meloxicam | 152 | 45 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 151 | 44 |
| Repatha Sureclick | Evolocumab | 149 | 36 |
| Simvastatin | Simvastatin | 149 | 37 |
| Eliquis | Apixaban | 148 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 143 | 24 |
| Famotidine | Famotidine | 142 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 141 | 46 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 139 | 38 |
| Allopurinol | Allopurinol | 136 | 40 |
| Lorazepam | Lorazepam | 135 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 130 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 129 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 128 | 44 |
| Memantine Hcl | Memantine Hcl | 122 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 122 | 37 |
| Atenolol | Atenolol | 121 | 34 |
| Sertraline Hcl | Sertraline Hcl | 119 | 40 |
| Buspirone Hcl | Buspirone Hcl | 118 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 109 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 107 | 34 |
| Pregabalin | Pregabalin | 107 | 21 |
| Methocarbamol | Methocarbamol | 103 | 43 |
| Clonazepam | Clonazepam | 102 | suppressed |
| Prednisone | Prednisone | 99 | 67 |
| Alprazolam | Alprazolam | 96 | 17 |
| Valsartan | Valsartan | 93 | 24 |
| Baclofen | Baclofen | 90 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 21 |
| Metformin Hcl Er | Metformin Hcl | 87 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 29 |
| Glimepiride | Glimepiride | 84 | 31 |
| Donepezil Hcl | Donepezil Hcl | 82 | 25 |
| Tresiba Flextouch U-100 | Insulin Degludec | 81 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 78 | 27 |
| Ibuprofen | Ibuprofen | 75 | 24 |
| Synthroid | Levothyroxine Sodium | 75 | 22 |
| Bumetanide | Bumetanide | 74 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 73 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 69 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 67 | 19 |
| Temazepam | Temazepam | 67 | suppressed |
| Glipizide | Glipizide | 66 | 23 |
| Celecoxib | Celecoxib | 63 | 17 |
| Promethazine Hcl | Promethazine Hcl | 63 | 19 |
| Mirtazapine | Mirtazapine | 62 | 19 |
| Bupropion Xl | Bupropion Hcl | 61 | 21 |
| Topiramate | Topiramate | 60 | 20 |
| Estradiol | Estradiol | 58 | 21 |
| Methylprednisolone | Methylprednisolone | 58 | 48 |
| Nystatin | Nystatin | 55 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 16 |
| Lovastatin | Lovastatin | 54 | 15 |
| Meclizine Hcl | Meclizine Hcl | 54 | 18 |
| Linzess | Linaclotide | 53 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | 13 |
| Ondansetron Odt | Ondansetron | 51 | 19 |
| Glipizide Er | Glipizide | 50 | 16 |
| Warfarin Sodium | Warfarin Sodium | 50 | 12 |
| Diazepam | Diazepam | 49 | 14 |
| Fluconazole | Fluconazole | 49 | 21 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 49 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 13 |
| Propranolol Hcl | Propranolol Hcl | 49 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 49 | 13 |
| Vraylar | Cariprazine Hcl | 48 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 18 |
| Finasteride | Finasteride | 45 | 13 |
| Xarelto | Rivaroxaban | 45 | 13 |
| Lansoprazole | Lansoprazole | 44 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 43 | 11 |
| Primidone | Primidone | 43 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 42 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 37 |
| Clonidine Hcl | Clonidine Hcl | 40 | 11 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 40 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | 15 |
| Torsemide | Torsemide | 40 | 11 |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 38 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 37 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 37 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 31 |
| Varenicline Tartrate | Varenicline Tartrate | 37 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | 13 |
| Spironolactone | Spironolactone | 35 | 11 |
| Lactulose | Lactulose | 34 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 29 |
| Mupirocin | Mupirocin | 34 | 20 |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 29 | 15 |
| Acyclovir | Acyclovir | 27 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 27 | 12 |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | suppressed |
| Victoza 3-Pak | Liraglutide | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Qulipta | Atogepant | 21 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 14 |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Dulera | Mometasone/Formoterol | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Prolia | Denosumab | 15 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,120.23 · 63 records | ABBVIE INC. | AJOVY, AREXVY, Auvelity, CAPLYTA, Cologuard Collection Kit, FANAPT, GEMTESA, Indigo System, JARDIANCE, Korlym, LEQVIO, MOUNJARO, Ohtuvayre, Omnipod, Ozempic, PAXLOVID, PRECIVITYAD2, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, WaveWriter Alpha Prime 16, Wegovy, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error